Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs

Gut

Volumn 48, Issue 4, 2001, Pages 571-577

  Nugent, S G ^b   Kumar, D ^b   Rampton, D S ^a   Evans, D F ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; AZO REDUCTASE; BALSALAZIDE; BICARBONATE; BUDENOFALK; BUDESONIDE; BUDESONIDE BETA DEXTRO GLUCURONIDE; CARBOHYDRATE; LACTIC ACID; MESALAZINE; OLSALAZINE; PREDNISOLONE; PRODRUG; SALAZOSULFAPYRIDINE; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

BACTERIAL METABOLISM; COLON FLORA; CROHN DISEASE; DIET; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; ENTERITIS; HUMAN; INTESTINE TRANSIT TIME; PH; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; BALLOON DILATATION; BIOLOGICAL AVAILABILITY; BUDESONIDE; ELECTRODES; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; REFERENCE VALUES; TELEMETRY;

EID: 0035084176     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.4.571     Document Type: Review

References (74)

1. Intraluminal pH of the human gastrointestinal tract
2. pH profile of gut as measured by radiotelemetry capsule
3. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device
4. Measurement of gastrointestinal pH profiles in normal ambulant human subjects
5. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device
6. Gastrointestinal pH profiles in ulcerative colitis
7. Very low intraluminal colonic pH in patients with active ulceradve colitis
8. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease
9. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: Colonic luminal pH in normal subjects and patients with Crohn's disease
10. Gastrointestinal pH profiles in patients with inflammatory bowel disease
11. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease
12. Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent 5-ASA containing capsules
13. An accurate, long-term, pH-sensitive radio pill for ingestion and implantation
14. Colonic mucosal pH in humans
15. Mucosal surface pH of the large intestine of the rat and of normal and inflamed large intestine in man
16. Intestinal obstruction caused by a Heidelberg capsule: Report of a case
17. Fecal lactate and ulcerative colitis
18. In vivo dialysis of faeces as a method of stool analysis. IV. The organic anion component
19. The colonic epithelium in ulcerative colitis: An energy-deficiency disease?
20. The effect of meat protein and dietary fibre on colonic function and metabolism
21. Effect of dietary fibre on colonic pH in healthy volunteers
22. The interrelations of faecal ammonia, pH and bicarbonate: Evidence of colonic absorption of ammonia by non-ionic diffusion
23. Is cholelithiasis an intestinal disease? A study of five inter-related factors
24. Faecal excretion of bicarbonate in ulcerative colitis
25. Colonic bicarbonate output as a test of disease activity in ulcerative colitis
26. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis
27. Luminal ions and short chain fatty acids as markers of functional activity of the mucosa in ulcerative colitis
28. Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis
29. Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: Increased glutamine metabolism in distal colon but no defect in butyrate metabolism
30. Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate
31. Butyrate absorption and lactate secretion in ulcerative colitis
32. Studies on the mechanism of bowel disturbance in ulcerative colitis
33. Upper intestinal motility in ulcerative colitis, idiopathic steatorrhoea, and the irritable colon
34. Abnormal motility of the small intestine in ulcerative colitis
35. Faecal stasis and diverticular disease in ulcerative colitis
36. Faecal stasis in proctocolitis
37. Colonic motility and transit in health and ulcerative colitis
38. An experiment to determine the active therapeutic moiety of sulphasalazine
39. Colonic release of 5-aminosalicylic acid slow release from an oral preparation in active ulcerative colitis
40. 5-aminosalicylic acid in a slow release preparation: Bioavailability, plasma levels, and excretion in humans
41. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously of released for absorption at different sites in the gastrointestinal tract
42. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease
43. Salicylates for inflammatory bowel disease
44. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease
45. Studies on the acetylating capacity of human colonic epithelial cells for 5-aminosalicylic acid
46. Delayed-release mesalazine (5-aminosalicylic acid): Coat dissolution and excretion in ileostomy subjects
47. Topical and systemic availability of 5-aminosalicylate: Comparisons of three controlled release preparations in man
48. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea
49. Release of 5-aminosalicyclic acid is reduced at pH below 5.4
50. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid delivering drugs during accelerated intestinal transit in healthy volunteers
51. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time
52. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation
53. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparison of intraluminal colonic concentrations, serum values, and urinary excretion
54. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis
55. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis
56. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis
57. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis
58. Ulcerative colitis practice guidelines in adults
59. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis
60. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis
61. Maintenance of remission of ulcerative colitis: A comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months
62. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
63. A comparison of budesonide and mesalamine for active Crohn's disease
64. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis
65. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
66. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine
67. A comparison of budesonide with prednisolone for active Crohn's disease
68. Budesonide versus prednisone in the treatment of active Crohn's disease
69. Entocort information pack
70. Principles of topical versus systemic corticoid treatment in inflammatory bowel disease
71. Budesonide-beta-D-glucuronide: A potential prodrug for treatment of ulcerative colitis
72. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis
73. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation